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Vitamin D Supplementation in Allo-HSCT Patients
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ABSTRACT
BACKGROUND: Bone health is a serious concern for long-term survivors of Allo-HSCT
due to multiple risk factors including steroids, chemotherapy, immunosuppressive
drugs, and poor nutrition status1. Steroids have been long proven to have negative
impact on bone health and the National Osteoporosis Foundation (NOF) lists steroids as
a contributing factor to osteoporosis and fractures. NOF guidelines recommend
providing adequate daily vitamin D as a safe and inexpensive way to help reduce
fracture risk1. Therefore, proper supplementation of vitamin D may increase the quality
of life for patients post Allo-HSCT.
PURPOSE: The purpose of this study is to determine if Allo-HSCT patients who receive
steroids as part of their treatment at Nebraska Medicine are being supplemented with
vitamin D.
METHODS: A retrospective review of electronic medical records was used to determine
if vitamin D supplementation was prescribed to patients who received steroids after
undergoing Allo-HSCT and whether this had an impact on their bone health, including
serum 25(OH)D levels, incidence of fractures/falls, DEXA scan results, and GVHD
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diagnosis. Inclusion criteria included adults who received Allo-HSCT from January 1,
2013 to December 31, 2014.
RESULTS: Out of 99 patients who underwent Allo-HSCT, 59 percent were prescribed
steroids of > 5 mg/day of prednisone or equivalent for > 3 months, compared to 41
percent who were not. Vitamin D supplementation was significantly different between
the two groups with 71 percent of the steroid group receiving vitamin D
supplementation compared to 40 percent of the non-steroid group (p=0.004). Diagnosis
of GVHD was also found to be statistically significant between groups with 90 percent of
the steroid group compared to 71 percent of the non-steroid group (p=0.016). Mortality
was found to be significantly higher in the non-steroid group compared to the steroid
group (p=0.005).
CONCLUSION: This study found 71 percent of patients who received steroids of > 5
mg/day of prednisone or equivalent for > 3 months, received vitamin D
supplementation. However, adequacy of vitamin D supplementation is still uncertain in
this patient population.
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CHAPTER 1: INTRODUCTION
Allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) is a proven
treatment for those suffering from malignant hematologic diseases of the blood or bone
marrow such as acute myeloid leukemia or myelodysplastic syndrome. Allo-HSCT
involves the transfer of stem cells from the donor to recipient, after their immune
systems have been wiped out by chemotherapy, radiation, or a combination of both.
The most significant risk of undergoing Allo-HSCT is the development of graft-versushost disease (GVHD). Studies have been conducted to evaluate supplementation of
vitamin D and improved survival rate of certain cancers and decreased risk of
developing GVHD2,3. However, there are few studies which evaluate supplementation of
vitamin D related to the use of steroids during Allo-HSCT. Steroids are proven to have
negative effects on the metabolism vitamin D, including inhibition of osteoblast
function, enhancement of bone resorption, inhibition of gastrointestinal calcium
absorption, and increase in urine calcium loss. To treat vitamin D deficiency, NOF
recommends adults be treated with 50,000 IU of vitamin D once a week or the
equivalent daily dose (7,000 IU vitamin D2 or vitamin D3 daily) for 8-12 weeks to achieve
normal (> 30 ng/mL) serum 25(OH)D concentrations 1. Overall, the nutrition status of
patients who undergo Allo-HSCT is extremely complex and unstable. For those patients
who are treated with steroids, it is important to prevent further deterioration of their
health and functional status by adequately supplementing vitamin D to ensure adequate
25(OH)D levels.
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CHAPTER 2: LITERATURE REVIEW
Vitamin D
Vitamin D is often categorized as a fat-soluble vitamin; however, it is not an
essential dietary factor as humans can produce it endogenously 4. More accurately,
vitamin D is closely related to a steroid hormone due to its molecular structure. Vitamin
D consists of two bioequivalent forms (ergocalciferol and cholecalciferol) both of which
are biologically inert until metabolized in the body5. Ergocalciferol (vitamin D2) is
obtained from dietary vegetable sources and oral supplements. Cholecalciferol (vitamin
D3) is obtained in fortified foods and oral supplements, but primarily through skin
exposure to ultraviolet B radiation in sunlight5. The skin produces vitamin D3
photochemically from 7-dehydrocholesterol, which is then metabolized in the liver to
produce 25-hydroxycholecalciferol (25[OH]D). Within the kidneys, 25(OH)D serves as a
substrate for 1-alpha-hydroxylase to make 1,25-dihydroxycholecalciferaol (1,25[OH]2D),
the biologically active form4. The biologically active form then has a significant role in
bone health. 1,25(OH)2D stimulates the absorption of calcium and phosphate from the
gut by opening calcium channels and stimulating the formation of calcium binding
proteins6. If 1,25(OH)2D concentrations drop due to deficiencies, less calcium is available
for bone mineralization. Parathyroid hormone (PTH) will then increase, stimulating the
hydroxylation of 25(OH)D in the kidney to produce more 1,25(OH) 2D. This increase in
PTH stimulates bone turnover and loss6. Therefore, vitamin D deficiency is known to
cause high bone turnover leading to osteoporosis, osteomalacia, falls and fractures.
(Figure 1)
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Figure 1: Pathophysiologic pathways from vitamin D deficiency to osteoporosis, osteomalacia,
falls and fractures.6

In the Longitudinal Aging Study Amsterdam (LASA) study which looked at serum
25(OH)D influences on serum PTH and parameters of bone health, serum osteocalcin
(maker for bone formation) and urinary deoxypyridinolin excretion (marker of bone
resorption), were shown to be elevated when serum 25(OHD) was low. Both markers
were shown to decrease with a rise in serum 25(OH)D levels up to 40 nmol/L (16.03
ng/dL)7. A placebo-controlled trial of 330 older women found a serum 25(OH)D level of
10 nmol/l (4 ng/mL) resulted in a risk ratio (RR) of hip fracture of 1.88. In a global study
of 7,441 postmenopausal women with osteoporosis there was a significant positive
relationship between serum 25(OH)D and bone mineral density (BMD) in the
trochanteric area of the hip, threshold below 50 nmol/L9.
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High bone turnover can then lead to increased risk of falls and fractures.
Epidemiological studies show a relationship between vitamin D deficiency and fractures.
In the LASA study incidence of fractures was higher when serum 25(OH)D was lower
than 30 nmol/L (12.01 ng/mL), and the lowest percentage of fractures was found with
serum 25(OH)D above 75 nmol/L (30 ng/mL) 10. In the Women’s Health Initiative study,
all women were treated with 1500mg/day of calcium citrate and 1000 IU/day of vitamin
D3 for 6 weeks11. The purpose of this study was to examine the effect of short term
calcium and vitamin D supplementation on biochemical markers of bone turnover. Their
analysis showed a significant decrease of hip fracture incidence and hip bone density
was found to be 1.06 percent higher in the calcium plus vitamin D group than in the
placebo (p<0.01)11.
Assessing Vitamin D
To determine vitamin D levels within the body, serum 25(OH)D concentrations
are assessed as the active form of vitamin D is physiologically regulated. 25(OH)D is the
key substrate for 1-alpha-hydroxylase to produce 1,25(OH)2D. Therefore, production of
1,25(OH)2D is directly dependent on the absolute concentrations of 25(OH)D. Currently
there is debate among research regarding adequate levels of serum 25(OH)D levels.
According to the Institute of Medicine, serum 25(OH)D levels of 20 ng/mL is considered
adequate for most individuals9. However, the Endocrine Society, International
Osteoporosis Foundation, American Geriatric Society, and NOF suggest a minimum level
of 30 ng/mL1,13-15. The debate regarding adequate serum 25(OH)D concentrations is
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based on adequate suppression of PTH concentrations to ensure intestinal absorption of
calcium does not lead to a decrease in serum calcium. In a prospective study of serum
25(OH)D level it was found baseline 25(OH)D levels were inversely associated with allcause mortality risk (adjusted hazard ratio [HR] = 0.95, 95% CI=0.92-0.98, per 10 nmol/L
[4 ng/mL] of 25[0H]D)16.
Vitamin D Supplementation
Vitamin D supplementation comes in two forms, ergocalciferol (vitamin D2) and
cholecalciferol (Vitamin D3). Vitamin D3 is the most efficient form of supplementation
as it has greater affinity for the vitamin D-binding protein and has a longer half-life (~3
weeks) compared to that of vitamin D2, therefore less frequent dosing may be
required18. In a meta-analysis of seven randomized control trials evaluating serum
25(OH)D concentrations after supplementation with vitamin D3 versus vitamin D2,
vitamin D3 was shown to increase serum 25(OH)D levels more efficiently (p=0.001)19.
However, at this time the NOF recommends either form of supplementation to reach
adequate serum 25(OH)D levels. The NOF recommends vitamin D intake for adults age
50 and older of 800-1000 IU per day, including supplementation if necessary 1. If a
patient is diagnosed with vitamin D deficiency (VDD) the NOF recommends adults be
treated with 50,000 IU of vitamin D once a week or the equivalent daily dose (7,000 IU
vitamin D2 or vitamin D3 daily) for 8-12 weeks to achieve serum 25(OH)D level of 30
ng/mL1. After this level is reached NOF recommends maintenance therapy to preserve
those concentrations1. However, determining adequate dosing should be individualized
based on a multitude of factors such as baseline serum 25(OH)D, absorptive capacity,
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and ability of liver to convert metabolites20. Therefore, Allo-HSCT patients likely require
higher dosages due to their multiple risk factors and complex health status. Regardless
of specific units of vitamin D supplementation, NOF and ACR guidelines, recommend
supplementing enough vitamin D to maintain adequate serum 25(OH)D levels, whatever
amount that may be1,17. Although severe vitamin D deficiencies are uncommon, the
2005-2006 NHANES study reported subclinical vitamin D deficiencies (defined as < 20
ng/mL) in 41.6% of their adult participants21. For generalized healthy adults, VDD may
not have any severe signs and symptoms, but for those who are undergoing treatment
for cancer, VDD may have more of an effect on their overall outcomes.
Vitamin D and Cancer
Research regarding vitamin D status and cancer has become of more interest in
recent years, with the potential role of vitamin D as an easily modifiable mediator of a
broad array of pathologic conditions, including cancer 22. In a prospective study which
looked at vitamin D status and cancer incidence in men, an increment of 25nmol/L (10
ng/mL) in predicted 25(OH)D level was associated with a 17% reduction in total cancer
incident (RR=0.83, 95% CI 0.74-0.92), a 29% reduction in total cancer mortality (RR=0.71,
95% CI 0.60-0.83), and a 45% reduction in digestive-system cancer mortality (RR=0.55,
95% CI 0.41-0.74)23. Another study looked at association between total average annual
sunlight and age-adjust breast cancer mortality rates in 87 regions of the U.S. Risk of
fatal breast cancer in the major urban areas of the U.S. was inversely proportional to
intensity of local sunlight (r=0.82, p=0.0001)24. In addition, a study which looked to
determine how many types of cancer are affected by solar radiation found the annual
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number of premature deaths (1970-1994) from cancer due to lower UV-B exposures
was 21,7000 (95% CI 20,400-23,400) for white Americans, 1400 (95% CI 1100-1600) for
black Americans and 500 (95% CI, 400-600) for Asian Americans and other mortalities25.
Vitamin D and GVHD
Significant research has also been completed looking at vitamin D
supplementation and its effect on GHVD, as GVHD is considered one of the most
significant complications of Allo-HSCT with detrimental impact on transplant related
mortality, overall survival, and patient quality of life25. According to research, Grade II-IV
acute GVHD in patients range from 20-50% and chronic GVHD from 40-50% after AlloHSCT26,27. In a retrospective cohort analysis, fifty-three patients’ serum 25(OH)D levels
were looked at prior to Allo-HSCT to determine correlation with risk of GVHD27. They
found the cumulative incidence of chronic GVHD at 2 years in patients with serum
25(OH)D levels <25 ng/mL was 63.8% compared to 23.8% in patients with levels >25
ng/mL (p=0.009)27. Additionally, in another retrospective analysis of 166 patients which
evaluated 25(OH)D levels before allo-HSCT found through multivariate analysis, vitamin
D level before transplant to be a significant independent risk factor for development of
chronic GVHD (cGVHD) (p=0.04)28. The RR of cGVHD at two years after transplant was
measure at 2.66 (95% CI 1.03-6.87) for 25(OH)D below 60 nmol/L compared with above
60 nmol/L (24 ng/mL) before transplant28.
Steroids and Allo-HSCT
Steroids, specifically glucocorticoids are often prescribed to patients undergoing
Allo-HSCT as they have an inhibitory effect on specific immune responses as well as
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suppressive effects which allow for management of inflammation or autoimmune
disorders29. While they have many benefits for those undergoing Allo-HSCT, they have
been proven to negatively impact bone health, causing decreased bone formation and
bone loss, reduce bone quality, and disrupt microarchitectural integrity 1. (Figure 2)

Figure 2. Pathophysiology of corticosteroid-induced osteoporosis31.

Glucocorticoid-induced osteoporosis is the most common form of secondary
osteoporosis, and needs to be considered in patients who receive Allo-HSCT due to their
fragile and complex health status30. Bone density declines rapidly at the beginning
stages of using steroids and then more slowly and steadily as steroid use continues 30.
Therefore, appropriate supplementation at the beginning of steroid use is critical. The
NOF lists glucocorticoids use of > 5 mg/d of prednisone or equivalent for > 3 months as a
risk factor for developing osteoporosis and fractures, as well as the point to which
supplementation of vitamin D should be initiated1. The American College of
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Rheumatology (ACR) recommends stricter guidelines, recommending patients taking
glucocorticoids at any dose or duration should receive vitamin D supplementation 17. In
this patient population in which steroids are often a standard form of treatment, it
would be important to take swift action in providing proper supplementation early on in
Allo-HSCT treatment. A prospective study of 146 patients who received Allo-HSCT found
that at two months after transplant, more than 50% of the patients had DEXA detected
osteoporosis, showing that subclinical bone abnormalities appear early post-HSCT32. The
same study found that duration of steroid use was a significant risk factor for developing
clinical bone complications as well (Hazards Ration [HR]: 1.06/month; 95% CI 1.00-1.14;
p=0.038)32.
Bone Mineral Density Assessment
To better assess patient’s bone mineral density and risk of fracture, dual energy
x-ray absorptiometry (DEXA) is considered the gold standard when determining bone
mineral density of the lumbar spine and hip. DEXA measurements of the hip and spine is
most often used to confirm a diagnosis of osteoporosis or predict future fracture risk 1.
Peak bone mass is achieved in early adulthood, followed by a declined which is
accelerated in women at menopause1. NOF recommends BMD testing be performed in
women age 65 and older and men age 70 and older. NOF continues to recommend BMD
testing by DEXA scan in post-menopausal women and men > 50 years of age if
prescribed short or long term glucocorticoid treatment1. Although there is no
consensus for optimal frequency of monitoring BMD, NOF guidelines suggest one to two
year BMD testing after initiating medical therapy for treatment of osteoporosis and
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every two years thereafter1. A study in 2001 assessed bone mineral density of 67 adult
patients who received stem cell transplants. Of those patients 49% were found to have
osteopenia and osteoporosis prior to transplant. There was also significant decrease in
T-score when comparing bone mineral density before transplant and at six months postHSCT (-1.23+ 1.08 compared to -1.87+ 1.28) (p<0.001)3. This study proposed the
demand for vitamin D is increased after Allo-HSCT, likely due to the multiple risk factors
this patient population carries, and supplementation of both calcium and vitamin D not
being prescribed outpatient3. As a result, this study encourages measurement of BMD
prior to transplant for baseline measurements.
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CHAPTER 3: METHODS
Participants and Study Design
This study was a retrospective chart review of data collect from the electronic
medical record. Inclusion criteria included age of 19 years or older and receiving an AlloHSCT at Nebraska Medicine from January 1, 2013 to December 31, 2014. Exclusion
criteria included children (less than 19 years of age) and those who received Auto-HSCT.
The Study protocol was approved by the Institutional Review Board at the University of
Nebraska Medical Center in Omaha, Nebraska. Ninety-nine patients were eligible for
this study.
Data Collection
Patients were identified with help of the Oncology/Hematology Transplant Data
Office at the University of Nebraska Medical Center. All data was collected between two
time points. The first time point, time of transplant, was defined as the day the patient
underwent Allo-HSCT (this included up to 30 days prior to transplant if labs or
information was gathered prior to the exact date of transplant). The second time point
was at the one year follow up appointment after receiving their transplant (this included
up to 15 months after their transplant as scheduling conflicts could have impacted their
“one year” follow-up). Baseline characteristics were gathered at time of transplant and
included age, sex, and race. Additional data was gathered between the time of
transplant and one year follow-up, this included: steroids prescribed, vitamin D
supplementation, serum 25(OH)D levels, documented falls/fractures, DEXA results, LOS,
and, mortality.
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Steroids
Prescribed steroids were gathered by review of the medications tab and a
keyword search of the term steroid within the medical record. The first classification of
steroid use was based on the NOF criterial for vitamin D supplementation which
specifies > 5 mg of prednisone or equivalent for >3 months for inclusion in the steroid
group. Patients did not have to be prescribed steroids consecutively to meet
requirements for duration of > 3 months. For example, if the patient was prescribed > 5
mg for six non-consecutive two week periods, they met criteria to be included in the
steroid group. All patients not meeting this criteria were placed in the non-steroid
groups. Therefore, if a patient received high dose steroids for one month they did not
meet criteria and were placed in the non-steroid group.
Steroid groups were later re-categorized based on ACR recommendations for
when vitamin D supplementation should be started. The steroid group was re-defined as
those who received any dose/duration of steroid during the first year following
transplant. Therefore, the patient who received high dose steroids for one month would
be included in the steroid group. The non-steroid group consisted of those who never
received any steroid between time of transplant and one year follow-up.
Vitamin D Supplementation
The primary outcome of the study was vitamin D supplementation.
Supplementation was found via the medications tab along with keyword search for
vitamin D in the medical chart. Use of a multivitamin was not considered as
supplemental vitamin D. Vitamin D supplementation was categorized into yes/no
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groups. Any dose or duration of vitamin D supplementation was placed in the yes group.
The no group consisted of those who did not receive any vitamin D supplementation
during time of transplant and one year follow-up.
Serum 25(OH)D
Serum 25(OH)D levels were collected from the “results review tab” within the
medical record, which is the location of all laboratory results in the electronic medical
record. All serum 25(OH)D levels were collected that occurred between date of
transplant and one year follow-up. Therefore, if a patient had five serum 25(OH)D levels
drawn during our study time points, all were recorded. However only the first serum
25(OH)D level was used in the analysis. Serum 25(OH)D levels were collected as
continuous variables and also categorized as “adequate” and “inadequate”. Adequate
was defined as > 30 ng/mL and inadequate was defined as < 30 ng/mL.
GVHD
Diagnosis of GVHD was found through keyword search in the medical chart.
Criteria for a diagnosis of GVHD was the documentation of diagnosis within a physician’s
note. GVHD diagnosis was categorized into yes/no groups. The yes group included acute
and chronic GVHD and any specified type (i.e. skin, liver, gut). Those without diagnosis
of GVHD within a physician’s note were placed in the no group.
Falls/Fractures
Documented falls and fractures were found through key word search in the
medical record. Only falls/fractures documented in physician or nursing notes during
the defined time period were gathered. Severity of fall/fracture was not collected and
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there was no differentiation if a patient had more than one fall/fracture. To meet
criteria for the yes group there needed to be at least one documentation in a physician
or nurse note stating the patient had a fall/fracture. Those who did not have
documentation of either were placed in the no group.
DEXA scan Results
DEXA results were collected between date of transplant and one year follow-up.
Results were found within the “results review tab” where non-laboratory tests are
reported. All DEXA results were collected between our two time-points. However, only
initial DEXA scans were used for analysis. DEXA results were categorized based on the
stated report within each scan. DEXA results at Nebraska Medicine describe bone health
in two ways: “increased risk of fracture” and “low risk for fracture”. Therefore, these
were the two categories used for the classification of patients in this study. Risk of
fracture was only categorized if patient underwent DEXA scanning. Therefore, if the
patient had documentation in the medical record of osteoporosis or osteopenia but did
not have a DEXA scan during our time of data collection, they were categorized as
missing data from our analysis.
Mortality
Mortality was collected between time of transplant and one year follow-up and
categorized a yes/no.
Length of Stay
Length of stay was defined as the length in days during the hospitalization to
undergo Allo-HSCT. This number was taken from day of admittance to day of discharge.
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This information was provided by the Oncology/Hematology Transplant Data Office.
Data Analysis
Descriptive statistics were calculated for all variables. Continuous variables were
represented by means and standard deviations and categorical variables were
represented as counts and percentages. The difference in means of the steroid vs. the
non-steroid groups were tested using Independent Sample T-Test. The difference in
proportion between steroid vs. the non-steroid group were evaluated with the ChiSquare Test or the Fischer’s Exact Test, as appropriate. Multivariate analysis was
preformed using Logistic Regression for those variables found to be significant through
the univariate analysis. Logistic regression established an odds ratio (OR) for select
variables of interest to determine if statistical significance remained independent of all
other variables. A Chi-squared test was used to compare the proportion of vitamin D
supplementation in both groups after re-categorizing steroid groups based on the ACR
guidelines. Data analysis was preformed using IBM SPSS Statistics 23 software and pvalues of < 0.05 were considered significant.
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CHAPTER 4: RESULTS
Ninety-nine patients were included in the study. Forty-five were female and 54
were male, ranging in age from 19 to 71 years of age, with a mean age of 49.7 years. The
majority of patients were Caucasian, compiling 94.5% of the population. Fifty-eight met
criteria for the steroid group while 41 were placed in the non-steroid group as seen in
Table 1.
Table 1: Steroid Groups
Steroid vs. Non-Steroid

N(%)

Steroid (>5 mg for > 3 months)

58 (59)

Non-Steroid

41 (41)

Total Patients

99

Baseline and clinical characteristics can be seen in Table 3 and 4 based. There
was no significant difference between steroid groups in age, sex, and race.
When assessing clinical characteristics based on steroid groups there was a
statistically larger percentage of vitamin D supplementation in the steroid group
compared to the non-steroid group (71% vs 41% respectively, p=0.04). GVHD diagnosis
was significantly different between the groups as well; with 90% in the steroid group
and 71% in the non-steroid group (p=0.016). Mortality was found to be statistically
significant between groups with 51% of the non-steroid group compared to only 24% of
those in the steroid group (p=0.005). Documented falls/fractures had a close trend to
significance with a p-value of 0.08, with 41% of the steroid group compared to 24% of
the non-steroid group having a documented falls or fracture. Serum 25(OH)D levels and
DEXA results did not have p-values of significance.
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Table 3: Continuous Variables Comparing Steroid Groups
Groups
Steroid (N=58)
Non-Steroid (N=41)

Variables (N)
Age, years
Serum 25(OH)D, ng/mL
Length of Stay, days

N

Mean (S.D.)

N

Mean (S. D.)

58
45
58

49.3 (13.26)
31.89 (16.32)
24.48 (5.66)

41
23
41

50.3 (13.69)
30.78 (18.05)
23.90 (6.47)

P
value
0.708
0.799
0.637

Table 4: Categorical Variables Comparing Steroid Groups
Groups
Steroid
(N=58)
Variable
Gender
Male
Female
Race
Caucasian
Other
Vitamin D Supplementation
Yes
No
25(OH)D
Adequate (> 30 ng/mL)
Inadequate (< 30 ng/mL)
GVHD Diagnosis
Yes
No
Falls/Fractures
Yes
No
DEXA Results
Increased Risk for Fracture
Low Risk for Fracture
Mortality
Yes
No

N

%

Non-steroid
(N= 41)
N
%

30
28

52
48

24
17

59
41

0.503

55
3

95
5

39
2

95
5

1.00

41
17

71
29

17
24

41
59

0.004

22
23

38
40

11
11

27
27

0.932

52
6

90
10

29
12

71
29

0.016

24
34

41
59

10
31

24
76

0.08

23
19

40
33

6
11

15
27

0.176

14
44

24
76

21
20

51
49

0.005

P Value
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Logistic regression was used to compare the two steroid groups and the
variables that were found to be significant through univariate analysis. Those found to
be significant include vitamin D supplementation, GVHD, and mortality. When
controlling for GVHD and mortality the odds of patients in the steroid group receiving
vitamin D supplementation are 2.952 times higher than the non-steroid group (p=0.019;
95% CI: 1.196-7.288). The odds of individuals being diagnosed with GVHD are 4.26 times
higher in the steroid group (p=0.014; 95% CI (1.333-13.651) when vitamin D
supplementation and mortality are controlled. Mortality was 3.004 times more likely to
occur in the non-steroid group comparatively when controlling for vitamin D
supplementation and GVHD (p=0.020; 95% CI (1.187-7.606) (Table 5).

Variable(s)

Table 5: Results of the Logistic Regression Model
p-value
OR
95% Confidence Interval (CI)

Vitamin D Supplementation

0.019

2.952

1.196-7.288

GVHD

0.014

4.267

1.333-13.651

Mortality

0.020

3.004

1.187-7.606

Additionally, an analysis was done to compare serum 25(OH)D levels between
patients who were supplemented vitamin D and those who were not supplemented
vitamin D. Out of 99 patients, 40 received vitamin D supplementation compared to 18
who did not. Overall there was no significant difference found between mean serum
25(OH)D levels between those who were supplemented and those who were not
supplemented.
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Table 6: Serum 25(OH)D Levels in Supplemented vs. Not Supplemented Patients
Groups
Supplemented
Non-Supplemented
(N=45)
(N=23)

Variables (N)

Serum 25(OH)D (ng/mL)

N

Mean (S.D.)

N

Mean (S. D.)

45

31.84 (17.06)

23

31.13 (16.56)

P
value
0.927

One final analysis was done in which steroid groups were re-categorized based
upon ACR recommendations for vitamin D supplementation. Using these redefined
groups, 93 individuals met criteria for the steroid group, leaving 6 in the non-steroid
group. Of those 93 patients in the steroid group, 60% received vitamin D
supplementation while 40% did not. Using a Fischer’s Exact test due to large discrepancy
in group sizes, no statistical significance was found between groups (p=0.228).

Table 7: Steroid groups categorized according to the ACR guidelines
Groups
Steroid
Non-steroid
(N=93)
(N=6)
Variable (Total N)
Vitamin D Supplementation
Yes
No

N

%

N

%

P
Value

56
37

60
40

2
4

33.5
66.5

0.228
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CHAPTER 5: DISCUSSION
The primary outcome of this research was to determine if Allo-HSCT patients
who received steroids > 5mg of prednisone or equivalent for > 3 months were
supplemented with vitamin D. We found that a significantly higher proportion of those
in the steroid group were supplemented with vitamin D compared to the non-steroid
group. Based on this, we can speculate that clinicians at Nebraska Medicine are aware
of the implications of steroid use in the Allo-HSCT population and are starting a
significant proportion of those patients on vitamin D supplementation as a result.
However, nearly a quarter of patients remained unsupplemented. This study did not
quantify the dose or duration of vitamin D supplementation which would have been
beneficial to determine if patients were receiving adequate amounts during and after
their transplant, which may be of relevance for future studies in this patient population.
As discussed in the literature review, standard prophylactic measurements for
bone health may not be enough to protect this patient population3. To gather more
information on vitamin D supplementation according to steroid regimen in our
population, we re-categorized groups based on ACR guidelines. Using these redefined
groups, which recommend vitamin D supplementation with any dose/duration of
steroid, it was found there was no statistical significance in vitamin D supplementation
between the steroid and non-steroid groups. Therefore, the same proportion of patients
were supplemented regardless of steroid use. The sample sizes of these two groups
were highly skewed with 93 patients in the steroid group and only 6 in the non-steroid
group. Therefore, 94% of our population received some dose/duration of steroid

21
between our defined time points, further demonstrating the need for vitamin D
supplementation. Allo-HSCT have increased need for vitamin D supplementation based
on multiple factors including steroid use, previous chemotherapy, lack of sun exposure,
and poor nutrition status1,20. While those in the non-steroid group were likely
appropriate for supplementation, it shows that patients who did not meet criteria for >
5mg of prednisone or equivalent for > 3 months were not being supplemented with
vitamin D. Therefore, if a patient received high dose steroids for one month they would
have likely not been prescribed vitamin D supplementation. A study by Petropoulou, et
al. found that at two months’ post-transplant more than 50% of patients had DEXA
detected osteoporosis, showing how critical early intervention is32.
Our secondary aim was to determine what clinical outcomes were associated
with steroid use of > 5mg of prednisone or equivalent for > 3 months. Based on review
of literature, we hypothesized that a significant proportion Allo-HSCT patients who
received steroids would also have inadequate serum 25(OH)D levels, documented
falls/fractures, DEXA results demonstrating increased risk for fracture, and diagnosis of
GVHD.
There was no statistical difference in proportions of patients with inadequate
serum 25(OH)D levels compared between steroid groups. There was also no significant
difference in mean serum 25(OH)D levels when compared between steroid and nonsteroid groups (31.89+16.32 vs 30.78+18.05, p=0.799). This could be explained by the
fact there was a significant portion of patients in the steroid group who were
supplemented with vitamin D, likely maintaining serum 25(OH)D levels or at least
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preventing a decrease. Both of our mean serum 25(OH)D levels were very similar and
met criteria for > 30 ng/mL. With that being said, out of 99 patients only 68 had initial
serum 25(OH)D levels drawn. Of those assessed, 50% had levels categorized as
inadequate. Overall, 33% of our patient population were never assessed for serum
25(OH)D levels, making it difficult to accurately evaluate differences between steroid
groups. Knowing the extensive risk factors Allo-HSCT patients carry, in the future it
would beneficial to have more consistent testing of serum 25(OH)D levels.
We also assessed mean serum 25(OH)D compared between supplemented and
non-supplemented groups, as supplementation of vitamin D is a better indicator of
serum 25(OH)D. Through this analysis, we found there was no significant difference
between supplemented and non-supplemented groups (31.84+17.06 vs 31.13+15.56,
p=0.927). Urbain, et al. found baseline 25(OH)D levels were 16.4+8.9 ng/mL in HSCT
patients33. Although our levels were not collected at baseline, they do show adequate
serum 25(OH)D levels between our two time points. It should also be noted the study
population of Allo-HSCT patients was predominately Caucasian, thus potentially
impacting our results as Caucasian individuals are at less risk for vitamin D deficiency
when compared to those with darker skin tones, such as African American or Hispanic
individuals1.
Falls and fractures between steroid groups were not found significant, however
did trend in that direction (p=0.08). This finding is of interest, given our small sample
size and the self-reported nature of this variable. Of the 34 documented falls or
fractures, 71% were in the steroid group compared to only 39% in the non-steroid
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group. The LASA study found incidence of fracture was higher when serum 25(OH)D was
lower than 30 nmol/L (12.01 ng/mL)10. They also found the lowest percentage of
fractures occurred with serum 25(OH)D levels were above 75 nmol/L (30 ng/mL) 10.
Knowing our mean serum 25(OH)D level for the steroid group was above 30 ng/mL
(31.89+16.32) and there was still a trend towards significance for falls and fractures, we
could propose our patient population may benefit from having serum 25(OH)D levels
above adequate.
When assessing DEXA screening between groups, 72% of those in the steroid
group underwent DEXA screening compared to 41% of the non-steroid group. Of those
patient’s in the steroid group, 55% were deemed to be at increased risk for fracture
compared to only 15% in the non-steroid group (p=0.176). This finding is similar to
Massenkeil, et al. which found 49% of HSCT patients to have osteopenia and
osteoporosis prior to transplant3. Out of the total 99 patients who received Allo-HSCT,
only 60% underwent DEXA scanning, leaving 40% of the population without an accurate
look at their bone density health. These findings suggest there is need for more
consistency when evaluating patients’ bone health. Massenkeil, et al. states it may be
beneficial for Allo-HSCT patients to receive DEXA scans prior to transplant and one year
after treatment has been started3. While NOF recommends BMD follow-up one year
after initiating treatment for osteoporosis1. In this patient population, we have room for
improvement with assessing and treating risk factors for decreased bone health.
Although there was a significant portion of those in the steroid group being
supplemented with vitamin D, there was also a trend towards significant for
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falls/fractures suggesting supplementation was not adequate to raise their 25(OH)D
levels to sufficient amounts. The lack of consistency in testing 25(OH)D levels and DEXA
scans as well made it difficult to find meaningful results.
GVHD diagnosis was statistically significant between steroid groups with 90% of
the steroid group being diagnosed with GVHD compared to 71% of the non-steroid
group (p=0.016). This can be explained as steroids are a common treatment for GHVD
disease. Therefore, these patients were likely diagnosed with GVHD and then started on
steroids. As we know pre-transplant 25(OH)D, specifically levels under <25 ng/mL, are
associate with increased risk of chronic GVHD 27,28. Therefore, it may be beneficial to
start assessing serum 25(OH)D levels prior to transplant and have their levels adequate
before starting transplant27.
Mortality was not a variable we had predicted to have statistical significance
when beginning our research. However, mortality was found to be significantly higher in
the non-steroid group compared to the steroid group, with 51% of the non-steroid
group compared to 24% of the steroid group (p=0.005). Initially, this finding seems
inconsistent from the information gathered from the literature review. It would have
seemed more likely that those in the steroid group would have a higher proportion of
mortality as they were likely being treated for complications from Allo-HSCT such as
GVHD. However, this finding could be explained by the fact these patients who died may
not have lived long enough to meet our requirements of the steroid group.
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Limitations
Inherently, this study has limitations. As it is a retrospective chart review, bias
may have occurred due to misclassification errors. The small sample size could have
shown less strength in association compared with a broader sample size. Another large
limitation to the study was the lack of consistency in drawing 25(OH)D levels along with
DEXA scanning. More consistent information regarding these outcomes could have
given us more detailed information to draw conclusions.
Applications for Clinical Practice
Development of this study came from clinical judgement regarding the risk
factors for decreased bone health in Allo-HSCT patients. It became apparent through
daily observation and clinical experience that these patients had multiple factors putting
their bone health at risk. Therefore, this study was developed in hopes to encourage use
of vitamin D supplementation. The results from this study are to show that while many
Allo-HSCT patients are being supplemented with vitamin D, there are inconsistencies in
dosage and objective testing to determine if supplementation is enough to prevent a
decline in bone health.
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CHAPTER 6: CONCLUSION
In conclusion, our study reports that 71% of patients who received steroids
according to NOF guidelines received vitamin D supplementation. Overall, it is
encouraging that over half of the patient population received vitamin D
supplementation. However, we do not know if supplementation was adequate for this
complex patient population due to the lack of consistency when treating and assessing
bone health. Further research should be completed to identify adequate amounts of
vitamin D supplementation in Allo-HSCT to maintain adequate serum 25(OH)D levels
and prevent deteriorating bone health in this complex patient population.
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